PALI - Market News Snapshot
2024-05-01 10:41:49 ET
DENVER, Colo., May 01, 2024 ( 247marketnews.com )- Brera Holdings (NASDAQ: BREA ), Palisade Bio, Inc. (Nasdaq: PALI ), Getaround (NYSE: GETR ), CytomX Therapeutics, Inc. (Nasdaq: CTMX ), and Predictive Oncology Inc. (NASDAQ: POAI ).
Brera Holdings (NASDAQ: BREA ) $1.49 +0.21 (+16.41%) responded to European media reports and Italian fan site posts stating that the Company is actively negotiating to purchase an Italian professional football (soccer) club.
24/7 Market News interviewed famed Investment Banker, Daniel McClory, who took a large position in Brera.
24/7- It appears that you beat everybody to the punch, concerning multi club professional sports team ownership via the public markets. What inspired you to move forward with Brera Holdings?
DM- While I’m passionate about sports, this is a business and the industry has a lot of unrealized upside, so I’m motivated by the economic fundamentals and I think that Brera Holdings is in the right place at the right time. Listing on Nasdaq as the first Italian football team to do so very early in Brera’s development of the MCO model created the publicly-traded platform to execute on all our other acquisitions, including our current focus on acquiring a Serie B club.
24/7- over the past week or two, I’ve seen Brera’s name mentioned in increasing Italian Media and club fan site reports. How is that progressing and why pick a Serie B club?
While I’m unable to provide any specifics, at this time, I’m more than happy to comment on Italian football’s rich history and culture. Italian professional football tends to be among the best and it’s experiencing a tremendous upswing, as its Serie A already secured one of the two additional UEFA Champions League spots. Serie B is a very strong and desirable league, but developing a Serie B club that’s capable of earning a Serie A promotion is our goal.
24/7- Speaking of landing the first punch, professional sport team ownership is in the midst of a financial sector Renaissance and leading investment banks, like Goldman Sachs and JP Morgan, established professional sports specific investment banking divisions. How will those moves affect the sports ownership and investment market and how do you plan to stay at the tip of the spear?
DM- The sports industry’s economic impact is already substantial, but it’s still growing, so it makes sense for these iconic investment banks to make their move.
As long as we remain true to our mission, democratizing the pro sport ownership opportunity for masses of Nasdaq investors, we should remain ahead of the curve, on many of our initiatives, and, frankly speaking, we plan to slide into the slipstream of some of the significant tailwinds that they’re going to produce, but look for Brera to find and exploit valuation arbitrages every day.
24/7- Deloitte, a leading consultancy firm, predicts that high-value sports properties will reach unprecedented valuations this year, with institutional investors keenly eyeing the industry for potential opportunities. What will it take for the masses to recognize these opportunities that have already captured the attention of many internationally recognized billionaires?
DM- I agree with their take and I’m sure that the projected explosion in interest is factored in their industry predications. Plus, professional sports are one of the most effective avenues for product marketing and sponsorships, which adds fuel to that fire, but I believe that the masses have already taken note and we’re providing an option for this expanding market.
24/7- What changes would you implement over the next year or two for Brera Holdings?
DM- We’re going to continue to push forward with our plan to acquire sports clubs that we believe have significant economic upside and strengthen our MCO strategy, but I think that one of our most important missions for the next two years is to capitalize on the unique convergence of events that should drive soccer’s popularity to the next level, especially in the US.
The Wrexham television series is attracting casual fans and providing a little background into the international professional soccer business, but that’s going to pale in comparison with what’s just around the corner. The US will be the epicenter of the football world, by hosting the 2024 Copa America, the 2025 FIFA Club World Cup, and the 2026 FIFA World Cup, which the experts project will explode the sport’s popularity.
Brera Advisory Board member Alan Rothenberg was in charge of the US hosting of the 1994 World Cup, which is widely considered to be the most successful ever, but this one could outdo that.
Considering that one of our key goals is to turn the growing fan base into our supporters and new stakeholders, I couldn’t think of a better set of upcoming market drivers.
Palisade Bio, Inc. (Nasdaq: PALI ) stated that it completed its analysis to determine the effects of bioactivated PALI-2108, Palisade’s orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug, on TNF-? production in a whole blood (WB) assay.
“These important data bolster our confidence in the robust anti-inflammatory potential of PALI-2108 in the management of UC,” stated Dr. Mitch Jones, CMO of Palisade Bio. “The superior efficacy of PALI-2108, as demonstrated by its lower half-maximal inhibitory concentration (or IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as a next-generation therapeutic option for patients with inflammatory bowel disease.”
Palisade is on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before the end of 2024.
Palisade Bio’s CEO, JD Finley, added “Our team’s exceptional operational execution is driving the clinical development of PALI-2108 towards our first-in-human study, which is on track to start later this year. We are committed to advancing our pioneering research initiatives aimed at improving the lives of patients suffering from UC and other inflammatory conditions.”
Getaround (NYSE: GETR ) reported that its existing Mudrick Capital Management debt facility was expanded to provide Getaround with up to $50 million in additional capital, of which $20 million was drawn down on April 29.
“Earlier this year we proactively transitioned our leadership team and began restructuring our operations to create what we believe is a long-term, sustainable business model in which we can confidently invest for profitable growth,” commented Eduardo Iniguez, CEO of Getaround. “These initiatives coupled with Mudrick Capital’s additional financial support underscore our commitment to car owners and renters who utilize our carsharing platform to meet society’s evolving mobility needs.”
“As I work with Eduardo and the reconstituted management team on Getaround’s vision for the future, I’m increasingly confident in the company’s ability to execute against its strategic growth and profitability plans,” stated Jason Mudrick, chief investment officer of Mudrick Capital Management and a member of the company’s board of directors. “Getaround’s unique competitive advantages and significant untapped market opportunities inspire my continuing support for the business plan through 2024 and beyond.”
CytomX Therapeutics, Inc. (Nasdaq: CTMX ) will report its first quarter 2024 results and provide an update on its initial CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a trial update on Wednesday, May 8, 2024, after the U.S. markets close, and host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Predictive Oncology Inc. (NASDAQ: POAI ) is developing a flu vaccine for the United States Department of Defense (DoD), in collaboration with FluGen.
“Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials,” claimed Paul Radspinner, President & Chief Executive Officer of FluGen. “The project looks to hold tremendous promise.”
“We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market,” sad Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. “Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients.”
The post Market News Snapshot appeared first on 24/7 MarketNews .
For further details see:
Market News Snapshot